Literature DB >> 11457826

Interleukin-1beta induces chronic activation and de novo synthesis of neutral ceramidase in renal mesangial cells.

R Franzen1, A Pautz, L Bräutigam, G Geisslinger, J Pfeilschifter, A Huwiler.   

Abstract

The lipid signaling molecule ceramide is formed by the action of acid and neutral sphingomyelinases and degraded by acid and neutral ceramidases. Short-term stimulation of mesangial cells with the pro-inflammatory cytokine interleukin-1beta (IL-1beta) leads to a rapid and transient increase in neutral sphingomyelinase activity (Kaszkin, M., Huwiler, A., Scholz, K., van den Bosch, H., and Pfeilschifter, J. (1998) FEBS Lett. 440, 163-166). In this study, we report on a second delayed peak of activation occurring after hours of IL-1beta treatment. This second phase of activation was first detectable after 2 h of treatment and steadily increased over the next 2 h, reaching maximal values after 4 h. In parallel, a pronounced increase in neutral ceramidase activity was observed, accounting for a constant or even decreased level of ceramide after long-term IL-1beta treatment, despite continuous sphingomyelinase activation. The increase in neutral ceramidase activity was due to expressional up-regulation, as detected by an increase in mRNA levels and enhanced de novo protein synthesis. The increase in neutral ceramidase protein levels and activity could be blocked dose- dependently by the p38 MAPK inhibitor SB 202190, whereas the classical MAPK pathway inhibitor U0126 and the protein kinase C inhibitor Ro 318220 were ineffective. Moreover, cotreatment of cells for 24 h with IL-1beta and SB 202190 led to an increase in ceramide formation. Interestingly, IL-1beta-stimulated neutral ceramidase activation was not reduced in mesangial cells isolated from mice deficient in MAPK-activated protein kinase-2, which is a downstream substrate of p38 MAPK, thus suggesting that the p38 MAPK-mediated induction of neutral ceramidase occurs independently of the MAPK-activated protein kinase-2 pathway. In summary, our results suggest a biphasic regulation of sphingomyelin hydrolysis in cytokine-treated mesangial cells with delayed de novo synthesis of neutral ceramidase counteracting sphingomyelinase activity and apoptosis. Neutral ceramidase may thus represent a novel cytoprotective enzyme for mesangial cells exposed to inflammatory stress conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11457826     DOI: 10.1074/jbc.M102153200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Essential roles of neutral ceramidase and sphingosine in mitochondrial dysfunction due to traumatic brain injury.

Authors:  Sergei A Novgorodov; Christopher L Riley; Jin Yu; Keith T Borg; Yusuf A Hannun; Richard L Proia; Mark S Kindy; Tatyana I Gudz
Journal:  J Biol Chem       Date:  2014-03-21       Impact factor: 5.157

2.  The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells.

Authors:  Cuiyan Xin; Shuyu Ren; Wolfgang Eberhardt; Josef Pfeilschifter; Andrea Huwiler
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 3.  Ceramidases, roles in sphingolipid metabolism and in health and disease.

Authors:  Nicolas Coant; Wataru Sakamoto; Cungui Mao; Yusuf A Hannun
Journal:  Adv Biol Regul       Date:  2016-10-11

Review 4.  Glycosphingolipids and cell death: one aim, many ways.

Authors:  Carmen Garcia-Ruiz; Albert Morales; José C Fernández-Checa
Journal:  Apoptosis       Date:  2015-05       Impact factor: 4.677

Review 5.  Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.

Authors:  Daniel Canals; David M Perry; Russell W Jenkins; Yusuf A Hannun
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

6.  Functions of neutral ceramidase in the Golgi apparatus.

Authors:  Wataru Sakamoto; Nicolas Coant; Daniel Canals; Lina M Obeid; Yusuf A Hannun
Journal:  J Lipid Res       Date:  2018-08-28       Impact factor: 5.922

Review 7.  Ceramide and ceramide 1-phosphate in health and disease.

Authors:  Lide Arana; Patricia Gangoiti; Alberto Ouro; Miguel Trueba; Antonio Gómez-Muñoz
Journal:  Lipids Health Dis       Date:  2010-02-05       Impact factor: 3.876

8.  Role of neutral ceramidase in colon cancer.

Authors:  Mónica García-Barros; Nicolas Coant; Toshihiko Kawamori; Masayuki Wada; Ashley J Snider; Jean-Philip Truman; Bill X Wu; Hideki Furuya; Christopher J Clarke; Agnieszka B Bialkowska; Amr Ghaleb; Vincent W Yang; Lina M Obeid; Yusuf A Hannun
Journal:  FASEB J       Date:  2016-09-08       Impact factor: 5.191

9.  Spinal ceramide and neuronal apoptosis in morphine antinociceptive tolerance.

Authors:  Leesa Bryant; Tim Doyle; Zhoumo Chen; Salvatore Cuzzocrea; Emanuela Masini; M Cristina Vinci; Emanuela Esposito; Emanuela Mazzon; Daniela Nicoleta Petrusca; Irina Petrache; Daniela Salvemini
Journal:  Neurosci Lett       Date:  2009-07-23       Impact factor: 3.046

Review 10.  Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate.

Authors:  Cungui Mao; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2008-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.